Novartis CEO sees IRA impact ‘manageable’ in short run, maintains midterm growth goal

As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act (IRA), Novartis CEO said the cost cuts “might be manageable” in the short term for the firm’s first few products to be included.